HK Stock MarketDetailed Quotes

SINOPHARM (01099)

Watchlist
  • 18.470
  • -0.310-1.65%
Market Closed Apr 30 16:07 CST
57.64BMarket Cap7.16P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

SINOPHARM (01099) Income Statement

All
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q9)Sep 30, 2025
(Q6)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
Turnover
-0.63%140.77B
-1.60%575.17B
-2.47%431.48B
-2.95%286.04B
-3.81%141.66B
-2.02%584.51B
-0.78%442.42B
-2.07%294.73B
1.20%147.27B
8.05%596.57B
Operating income
-0.63%140.77B
-1.60%575.17B
-2.47%431.48B
-2.95%286.04B
-3.81%141.66B
-2.02%584.51B
-0.78%442.42B
-2.07%294.73B
1.20%147.27B
8.05%596.57B
Cost of sales
----
1.25%-533.5B
----
2.60%-265.7B
----
1.42%-540.25B
----
1.76%-272.78B
----
-8.59%-548.06B
Operating expenses
0.29%-131.4B
1.25%-533.5B
2.23%-400.21B
2.60%-265.7B
3.59%-131.78B
1.42%-540.25B
0.34%-409.34B
1.76%-272.78B
-1.57%-136.69B
-8.59%-548.06B
Gross profit
-5.25%9.36B
-5.84%41.67B
-5.50%31.27B
-7.28%20.35B
-6.55%9.88B
-8.77%44.26B
-5.99%33.09B
-5.70%21.94B
-3.34%10.58B
2.27%48.51B
Selling expenses
6.21%-3.6B
5.70%-16.18B
7.45%-11.84B
7.48%-7.84B
8.66%-3.84B
1.79%-17.16B
-1.11%-12.79B
-0.54%-8.48B
-1.75%-4.21B
-4.50%-17.47B
Administrative expenses
6.32%-1.49B
6.85%-7.84B
8.85%-4.85B
6.30%-3.67B
9.07%-1.59B
3.05%-8.41B
2.84%-5.33B
1.33%-3.92B
-0.84%-1.75B
-6.04%-8.68B
Research and development expenses
26.35%-46.59M
----
11.76%-172.61M
----
11.07%-63.26M
----
24.99%-195.61M
----
25.87%-71.13M
----
Profit from asset sales
-24.40%3.48M
34.20%-1.04B
131.58%24.39M
----
38.56%4.61M
23.49%-1.58B
-96.73%10.53M
----
-85.73%3.33M
-6.80%-2.07B
Revaluation surplus
44.00%-9.44K
----
-203.11%-3.26M
----
-180.65%-16.85K
----
3,176.15%3.16M
----
135.67%20.9K
----
-Changes in the fair value of other assets
44.00%-9.44K
----
-203.11%-3.26M
----
-180.65%-16.85K
----
3,176.15%3.16M
----
135.67%20.9K
----
Impairment and provision
0.72%-949.02M
27.44%-1B
-8.91%-1.94B
-5.45%-1.39B
-6.03%-955.91M
-107.11%-1.38B
-9.74%-1.78B
-1.98%-1.32B
-14.48%-901.55M
-0.07%-666.97M
-Other impairment is provision
0.72%-949.02M
27.44%-1B
-8.91%-1.94B
-5.45%-1.39B
-6.03%-955.91M
-107.11%-1.38B
-9.74%-1.78B
-1.98%-1.32B
-14.48%-901.55M
-0.07%-666.97M
Special items of operating profit
7.48%293.21M
-8.56%428.51M
141.02%977.92M
91.72%-1.01M
28.00%272.82M
-19.48%468.62M
-29.40%405.75M
-768.52%-12.17M
-27.35%213.15M
-13.92%582.01M
Operating profit
-4.10%3.24B
-0.93%16.04B
0.56%12.43B
-9.44%7.45B
-4.00%3.38B
-19.90%16.19B
-18.03%12.36B
-14.19%8.22B
-16.01%3.52B
-1.92%20.21B
Financing income
----
-18.92%500.25M
----
-34.56%254.85M
----
-17.00%616.97M
----
11.17%389.45M
----
36.96%743.37M
Financing cost
----
15.28%-2.5B
----
14.56%-1.25B
----
7.20%-2.95B
----
17.24%-1.46B
----
14.98%-3.17B
Share of profits of associates
----
2.81%1.23B
----
10.21%686.63M
----
7.64%1.2B
----
9.05%623.03M
----
4.46%1.11B
Share of profit from joint venture company
----
-3.12%2.83M
----
-27.41%1.23M
----
169.16%2.92M
----
-43.27%1.69M
----
-244.88%-4.22M
Special items of earning before tax
306.38%39.6M
54.98%-476.59M
1,104.58%12.44M
140.76%71.73M
-64.84%9.74M
-269.12%-1.06B
93.64%-1.24M
-237.28%-176M
635.15%27.71M
660.80%625.97M
Earning before tax
-1.53%2.9B
5.70%14.8B
0.43%10.88B
-5.09%7.21B
-5.73%2.94B
-28.25%14B
-16.82%10.84B
-14.32%7.6B
-14.15%3.12B
5.11%19.51B
Tax
----
-10.84%-3.97B
----
-10.33%-1.87B
----
20.55%-3.58B
----
13.97%-1.7B
----
-6.73%-4.5B
After-tax profit from continuing operations
-3.06%2.19B
3.94%10.83B
-3.40%8.1B
-9.53%5.34B
-5.93%2.26B
-30.55%10.42B
-16.67%8.39B
-14.42%5.9B
-14.65%2.4B
4.63%15.01B
Earning after tax
-3.06%2.19B
3.94%10.83B
-3.40%8.1B
-9.53%5.34B
-5.93%2.26B
-30.55%10.42B
-16.67%8.39B
-14.42%5.9B
-14.65%2.4B
4.63%15.01B
Minority profit
-3.26%772.93M
9.05%3.68B
-10.07%2.8B
-14.75%1.87B
-18.32%798.98M
-43.35%3.37B
-21.67%3.11B
-21.28%2.2B
-19.80%978.14M
2.34%5.96B
Profit attributable to shareholders
-2.95%1.41B
1.50%7.16B
0.53%5.31B
-6.43%3.47B
2.59%1.46B
-22.14%7.05B
-13.41%5.28B
-9.76%3.7B
-10.70%1.42B
6.19%9.05B
Basic earnings per share
-4.26%0.45
1.33%2.29
0.59%1.7
-6.72%1.11
2.17%0.47
-22.07%2.26
-13.78%1.69
-9.85%1.19
-9.80%0.46
6.23%2.9
Diluted earnings per share
-4.26%0.45
1.33%2.29
0.59%1.7
-6.72%1.11
2.17%0.47
-22.07%2.26
-13.78%1.69
-9.85%1.19
-9.80%0.46
6.23%2.9
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
Tianjian International Certified Public Accountants LLP, Tianjian Certified Public Accountants (Special General Partnership)
--
--
--
Tianjian International Certified Public Accountants LLP, Tianjian Certified Public Accountants (Special General Partnership)
--
--
--
PwC, PwC Zhongtian Certified Public Accountants (Special General Partnership)
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q9)Sep 30, 2025(Q6)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023
Turnover -0.63%140.77B-1.60%575.17B-2.47%431.48B-2.95%286.04B-3.81%141.66B-2.02%584.51B-0.78%442.42B-2.07%294.73B1.20%147.27B8.05%596.57B
Operating income -0.63%140.77B-1.60%575.17B-2.47%431.48B-2.95%286.04B-3.81%141.66B-2.02%584.51B-0.78%442.42B-2.07%294.73B1.20%147.27B8.05%596.57B
Cost of sales ----1.25%-533.5B----2.60%-265.7B----1.42%-540.25B----1.76%-272.78B-----8.59%-548.06B
Operating expenses 0.29%-131.4B1.25%-533.5B2.23%-400.21B2.60%-265.7B3.59%-131.78B1.42%-540.25B0.34%-409.34B1.76%-272.78B-1.57%-136.69B-8.59%-548.06B
Gross profit -5.25%9.36B-5.84%41.67B-5.50%31.27B-7.28%20.35B-6.55%9.88B-8.77%44.26B-5.99%33.09B-5.70%21.94B-3.34%10.58B2.27%48.51B
Selling expenses 6.21%-3.6B5.70%-16.18B7.45%-11.84B7.48%-7.84B8.66%-3.84B1.79%-17.16B-1.11%-12.79B-0.54%-8.48B-1.75%-4.21B-4.50%-17.47B
Administrative expenses 6.32%-1.49B6.85%-7.84B8.85%-4.85B6.30%-3.67B9.07%-1.59B3.05%-8.41B2.84%-5.33B1.33%-3.92B-0.84%-1.75B-6.04%-8.68B
Research and development expenses 26.35%-46.59M----11.76%-172.61M----11.07%-63.26M----24.99%-195.61M----25.87%-71.13M----
Profit from asset sales -24.40%3.48M34.20%-1.04B131.58%24.39M----38.56%4.61M23.49%-1.58B-96.73%10.53M-----85.73%3.33M-6.80%-2.07B
Revaluation surplus 44.00%-9.44K-----203.11%-3.26M-----180.65%-16.85K----3,176.15%3.16M----135.67%20.9K----
-Changes in the fair value of other assets 44.00%-9.44K-----203.11%-3.26M-----180.65%-16.85K----3,176.15%3.16M----135.67%20.9K----
Impairment and provision 0.72%-949.02M27.44%-1B-8.91%-1.94B-5.45%-1.39B-6.03%-955.91M-107.11%-1.38B-9.74%-1.78B-1.98%-1.32B-14.48%-901.55M-0.07%-666.97M
-Other impairment is provision 0.72%-949.02M27.44%-1B-8.91%-1.94B-5.45%-1.39B-6.03%-955.91M-107.11%-1.38B-9.74%-1.78B-1.98%-1.32B-14.48%-901.55M-0.07%-666.97M
Special items of operating profit 7.48%293.21M-8.56%428.51M141.02%977.92M91.72%-1.01M28.00%272.82M-19.48%468.62M-29.40%405.75M-768.52%-12.17M-27.35%213.15M-13.92%582.01M
Operating profit -4.10%3.24B-0.93%16.04B0.56%12.43B-9.44%7.45B-4.00%3.38B-19.90%16.19B-18.03%12.36B-14.19%8.22B-16.01%3.52B-1.92%20.21B
Financing income -----18.92%500.25M-----34.56%254.85M-----17.00%616.97M----11.17%389.45M----36.96%743.37M
Financing cost ----15.28%-2.5B----14.56%-1.25B----7.20%-2.95B----17.24%-1.46B----14.98%-3.17B
Share of profits of associates ----2.81%1.23B----10.21%686.63M----7.64%1.2B----9.05%623.03M----4.46%1.11B
Share of profit from joint venture company -----3.12%2.83M-----27.41%1.23M----169.16%2.92M-----43.27%1.69M-----244.88%-4.22M
Special items of earning before tax 306.38%39.6M54.98%-476.59M1,104.58%12.44M140.76%71.73M-64.84%9.74M-269.12%-1.06B93.64%-1.24M-237.28%-176M635.15%27.71M660.80%625.97M
Earning before tax -1.53%2.9B5.70%14.8B0.43%10.88B-5.09%7.21B-5.73%2.94B-28.25%14B-16.82%10.84B-14.32%7.6B-14.15%3.12B5.11%19.51B
Tax -----10.84%-3.97B-----10.33%-1.87B----20.55%-3.58B----13.97%-1.7B-----6.73%-4.5B
After-tax profit from continuing operations -3.06%2.19B3.94%10.83B-3.40%8.1B-9.53%5.34B-5.93%2.26B-30.55%10.42B-16.67%8.39B-14.42%5.9B-14.65%2.4B4.63%15.01B
Earning after tax -3.06%2.19B3.94%10.83B-3.40%8.1B-9.53%5.34B-5.93%2.26B-30.55%10.42B-16.67%8.39B-14.42%5.9B-14.65%2.4B4.63%15.01B
Minority profit -3.26%772.93M9.05%3.68B-10.07%2.8B-14.75%1.87B-18.32%798.98M-43.35%3.37B-21.67%3.11B-21.28%2.2B-19.80%978.14M2.34%5.96B
Profit attributable to shareholders -2.95%1.41B1.50%7.16B0.53%5.31B-6.43%3.47B2.59%1.46B-22.14%7.05B-13.41%5.28B-9.76%3.7B-10.70%1.42B6.19%9.05B
Basic earnings per share -4.26%0.451.33%2.290.59%1.7-6.72%1.112.17%0.47-22.07%2.26-13.78%1.69-9.85%1.19-9.80%0.466.23%2.9
Diluted earnings per share -4.26%0.451.33%2.290.59%1.7-6.72%1.112.17%0.47-22.07%2.26-13.78%1.69-9.85%1.19-9.80%0.466.23%2.9
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --Tianjian International Certified Public Accountants LLP, Tianjian Certified Public Accountants (Special General Partnership)------Tianjian International Certified Public Accountants LLP, Tianjian Certified Public Accountants (Special General Partnership)------PwC, PwC Zhongtian Certified Public Accountants (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.99%
Sample Name
Sample Code
 +4.00%
Sample Name
Sample Code
 +2.86%
4
SINOPEC CORP
00386
+2.22%
5
CNOOC
00883
+1.66%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +46.25%
Sample Name
Sample Code
 +33.47%
Sample Name
Sample Code
 +26.48%
4
Loongson Technology Corporation
688047
+24.63%
5
Rockchip Electronics
603893
+19.54%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -